newsfilter
← Latest News
Business Wire·

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

– On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31,